PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer.
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. However, development of T-cell engagers has been limited due to challenges with efficacy and safety. To address these challenges, we have developed a comprehensive T-cell engager platform to enable custom design and optimization of molecules based on a target product profile.
Learn more about our TCE platform.
AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s platform integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development.